{"analyses":[{"ciLowerLimit":"0.551","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.913","groupDescription":"TC1/2/3 or IC1/2/3 ITT-WT","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0073","paramType":"Hazard Ratio (HR)","paramValue":"0.709","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.484","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.907","groupDescription":"TC2/3 or IC2/3 Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Unstratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0097","paramType":"Hazard Ratio (HR)","paramValue":"0.662","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.5","upperLimit":"40.0","value":"26.1"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"22.9","value":"17.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"116"}],"units":"Participants"}],"title":"TC2/3 or IC2/3 Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.2","upperLimit":"28.1","value":"24.4"},{"groupId":"OG001","lowerLimit":"11.2","upperLimit":"20.1","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"title":"TC1/2/3 or IC1/2/3 Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"OS in Arm A Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG001","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"PD-L1 WT populations are defined as the PD-L1 populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with an activating EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Baseline until death (up approximately 53 months)","title":"OS in Arm A Versus Arm C by PD-L1 Subgroup","type":"SECONDARY","unitOfMeasure":"Months"}